On Nov. 9, it released earnings and updates on its candidate.
“This has been an exciting period for Arcturus highlighted by our preliminary ARCT-021 Phase 1/2 COVID-19 vaccine study results. These data, as well as those from our ARCT-810 Phase 1 study, illustrate a highly productive period of clinical advancement of our novel mRNA based therapeutic candidates. The ARCT-021 Phase 1/2 data provide clinical validation for our unique vaccine candidate and suggest that our self-replicating mRNA-based investigational vaccine could have a differentiated clinical profile and may allow vaccination at low doses. We believe that ARCT-021 could play an important role in the massive global vaccination campaigns that will be necessary to control the COVID-19 pandemic. We look forward to rapidly moving ARCT-021 forward in later-stage clinical studies,” said Joe Payne, CEO of Arcturus.
Payne joined TheStreet to talk about the company's vaccine candidate and why the company is pursuing a candidate that will come in powdered form and therefore won't need to be frozen like other vaccine candidates from companies such as Moderna (MRNA) - Get Moderna, Inc. Report or Pfizer (PFE) - Get Pfizer Inc. Report.